CRISPR THERAPEUTICS AG: operating income or loss
Operating income or loss for CRISPR THERAPEUTICS AG. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All CRISPR THERAPEUTICS AG financial histories
What this measure means
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
Exact concept: us-gaap:OperatingIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -664,571,000 | USD | 2026-02-12 | 10-K · 0001193125-26-048957 |
| 2024-01-01 | 2024-12-31 | -466,566,000 | USD | 2026-02-12 | 10-K · 0001193125-26-048957 |
| 2023-01-01 | 2023-12-31 | -222,538,000 | USD | 2026-02-12 | 10-K · 0001193125-26-048957 |
| 2022-01-01 | 2022-12-31 | -673,161,000 | USD | 2025-02-11 | 10-K · 0000950170-25-017899 |
| 2021-01-01 | 2021-12-31 | 373,528,000 | USD | 2024-02-21 | 10-K · 0000950170-24-017571 |
| 2020-01-01 | 2020-12-31 | -354,435,000 | USD | 2023-02-21 | 10-K · 0000950170-23-003441 |
| 2019-01-01 | 2019-12-31 | 46,740,000 | USD | 2022-02-15 | 10-K · 0000950170-22-001282 |
| 2018-01-01 | 2018-12-31 | -158,943,000 | USD | 2021-02-16 | 10-K · 0001564590-21-006074 |
| 2017-01-01 | 2017-12-31 | -64,648,000 | USD | 2020-02-12 | 10-K · 0001564590-20-004355 |
| 2016-01-01 | 2016-12-31 | -68,130,000 | USD | 2019-02-25 | 10-K · 0001564590-19-004115 |
| 2015-01-01 | 2015-12-31 | -25,729,000 | USD | 2018-03-08 | 10-K · 0001564590-18-004920 |
| 2014-01-01 | 2014-12-31 | -6,627,000 | USD | 2017-03-10 | 10-K · 0001564590-17-003977 |
Related financial histories
- CRISPR THERAPEUTICS AG: total assets
- CRISPR THERAPEUTICS AG: total liabilities
- CRISPR THERAPEUTICS AG: stockholders equity
- CRISPR THERAPEUTICS AG: cash and cash equivalents
- CRISPR THERAPEUTICS AG: net income or loss
- CRISPR THERAPEUTICS AG: operating cash flow
- CRISPR THERAPEUTICS AG: capital expenditure payments
- CRISPR THERAPEUTICS AG: revenue
- CRISPR THERAPEUTICS AG: contract revenue excluding tax
- CRISPR THERAPEUTICS AG: financing cash flow
- CRISPR THERAPEUTICS AG: investing cash flow
- CRISPR THERAPEUTICS AG: retained earnings or deficit
- CRISPR THERAPEUTICS AG: basic weighted-average shares
- CRISPR THERAPEUTICS AG: diluted weighted-average shares
- CRISPR THERAPEUTICS AG: basic earnings per share
- CRISPR THERAPEUTICS AG: diluted earnings per share
- CRISPR THERAPEUTICS AG: income tax expense or benefit
- CRISPR THERAPEUTICS AG: net property, plant and equipment
- CRISPR THERAPEUTICS AG: share-based compensation expense
- CRISPR THERAPEUTICS AG: current assets
- CRISPR THERAPEUTICS AG: current liabilities
- CRISPR THERAPEUTICS AG: current accounts payable
- CRISPR THERAPEUTICS AG: net finite-lived intangible assets
- CRISPR THERAPEUTICS AG: net current accounts receivable
- CRISPR THERAPEUTICS AG: operating expenses
- CRISPR THERAPEUTICS AG: research and development expense
Inspect the source
- Entity
- CRISPR THERAPEUTICS AG / CIK 0001674416
- Captured
- 2026-09-21T17:23:00.064Z
- SEC response SHA-256
bb57dd5f2b124e21e027bdcf9d925a06e9aa25cb8b2e84515ef679c3b5c3c413
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001674416.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))